Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-10
2008-06-10
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S439000, C424S001130
Reexamination Certificate
active
07384971
ABSTRACT:
New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3′diindolylmethane (LTr-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia, endometriosis and HPV-related conditions including cervical dysplasia.
REFERENCES:
patent: 5830887 (1998-11-01), Kelly
patent: 5895787 (1999-04-01), Arffmann et al.
patent: 5948808 (1999-09-01), Safe
patent: 5981568 (1999-11-01), Kunz et al.
patent: 6001868 (1999-12-01), Firestone et al.
patent: 6086915 (2000-07-01), Zeligs
patent: 6399645 (2002-06-01), Bell et al.
patent: 6534085 (2003-03-01), Zeligs
patent: 6613792 (2003-09-01), Ellenberger et al.
patent: 6689387 (2004-02-01), Zeligs
patent: 2002/0147155 (2002-10-01), Foster et al.
patent: 2003/0096855 (2003-05-01), Zeligs
patent: 2004/0072891 (2004-04-01), Zeligs
patent: 2004/0156910 (2004-08-01), Zeligs
Liang Jin et al (Liang, j. et al. cancer research 1999, 59, 3991-3997).
Baugh SM et al., “Treatment of cervical dysplasia with indole-3-carbinol” in The Ray A. Barlow Scientific Symposium, Jan. 23, 1998, Shreveport : The Center for Excellence in Cancer Research, Treatment and Education, Louisiana State University Medical Center, Shreveport (LA), p. 3.
Bell, MC et al., “Placebo-controlled Trial of Indole-3-Carbinol in the Treatment of Cervical Dysplasia”, Mar. 1999, Gynecol. Oncol. 72:446.
Yuan F et al., “Prevention of Papillomavirus initiated cancer by the phytochemical Indole-3-Carbinol”, Proceedings of the 17thInternational Papillomavirus Conference, Jan. 9-15, 1999, p. 73.
BioResponse-DIM Indolplex Product Information Brochure, Dec. 15, 1998.
Dec. 1998 Bioresponse Letter, Dec. 29, 1998.
Zeligs MA, “Diet and Estrogen Status: The Cruciferous Connection”, 1998, J Med Food, 1:67-82.
Ponten J and Guo Z, “Precancer of the Human Cervix ”, 1998, Cancer Surveys 32:201-229.
Cancer Medicine 3rd edition, 1993, JF Holland ed., Lea & Febiger, Malvern, PA p. 1633.
Molecular Biology of the Cell 2nded., 1989, Alberts, B et al., Garland Publishing, Inc., New York, pp. 1193-1194, 1204-1206.
Arbeit, JM et al., “Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice”, Apr. 1996, Proc Natl Acad Sci, USA 93:2930-2935.
Bell, MC et al., “Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN”, 2000, Gynecologic Oncology, 78:123-129.
Bradfield et al., “High-performance liquid chromatographic anaylsis of anticarcinogenic indoles inBassica oleracea”, 1987, J Agric Food Chem 35:46-49.
Michnovicz et al., “Changes in levels of urinary extrogen metabolites after oral indole-3-carbinol treatment in humans”, 1997, J Natl Cancer Inst 89:718-23.
Ho et al., “Urinary 2/16 alpha-hydroestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and and potential biomarker of breast cancer risk”, 1998, Ann Acad Med Singapore 27:294-9.
Schneider et al., “Abnormal oxidative metabolism of estradiol in women with breast cancer”, 1982, Proc Natl Acad Sci USA 79:3047-52.
Bradlow et al., “2-hydroxyestrone: the ‘good’ estrogen”, J Endocrin 150:S259-S265.
Komura et al., “Catecholestrogen as a natural antioxidant”, 1996, Ann NY Acad Sci 786:419-29.
Rosen et al., “Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis”, 1998, Otolaryngol Head Neck Surg 118:810-5.
Jin et al., “Indole-3-carbinol prevents cervical cancer in human papillomavirus type 16 (HPV16) transgenic mice”, 1999, Cancer Res 59″3991-7.
Chen et al., “aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindoylmethane”, 1998, Carcinogenesis 19:1631-1639.
Auborn et al., 2000, “Treatment of Human Papillomavirus Gynecologic Infections”, Clin Lab Med 20:407-22.
Bradlow et al. “Multifunctional aspects of the action of indole-3-carbinol as an anyi-tumor agent,” Annals of New York Academy of Sciences, 1999, vol. 889, pp. 204-213.
Chang et al., 1999, “Cytostatic and antiestrogenic effects of 2-(Indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol,” Biochem. Pharmacol. 58:825-834.
Dashwood, R.H., 1998, “Indole-3-carbinol: anticarcinogen or tumor promoter inbrassicavegetables?” Chem Biol. Interact., 110(1-2):1-5.
de Vet et al., 1994, “The role of cigarette smoking in the etiology of cervical dysplasia,” Epidemiology 5:631-633.
Exon, et al., 2000, “Dietary indole-3-carbinol alters immune functions in rats,” J. Toxicol. Environ. Health A., 59(4):271-9.
Gillner et al., 1985, “Interactions of indoles with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat lier,” Mol Pharmacol 28:357-363.
Gooptu et al., 2000, “Treatment of viral warts with cimetidine: and open-label study,” Clin. Exp. Dermatol. 25(3):183-5.
Hardman, et al. “Goodman & Gilman's The Pharmacological Basis of Therapeutics” (9thed, 1996) pp. 51 and 57-58.
Larson-Su et al., 2001, “Transplacental exposure to indole-3-carbinol induces sex-specific expression of CYP1A1 and CYP1B1 in the liver of Fischer 344 neonatal rats,” Toxicological Sci. 64:162-168.
Liu et al., 1994, “Indolo[3,2-b]carbozole: a dietary-derived factor the exhibits both antiestrogenic and estrogenic activity,” J. Natl. Cancer Inst. 86:1758-1765.
Loub et al., 1975, “Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants,” J. Natl. Cancer Inst. 54:985-988.
Michnovicz et al., 1991, “Cimetidine inhibits catechol estrogen metabolism in women,” Metabolism, 40(2):170-74.
Michnovicz et al., 1986, “Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estorgenic effect of cigarette smoking,” N Engl J Med 315:1305-1309.
Michnovicz et al., 1988, “Increased urinary catechol estrogen excretion in female smokers,” Steroids 52:69-83.
Riby et al., 2000, “Ligand-independent activation of estrogen receptor function by 3,3′-diindolylmethane in human breast cancer cells,” Biochem. Pharmacol. 60:167-177.
Ritter et al., 2001, “Oxidations of 17beta-estradiol and estrone and their interconversions catalyzed by liver, mammary gland and mammary tumor after acute and chronic treatment of rats with indole-3-carbinol or beta-naphthoflavine,” Can. J. Physiol. Pharmacol. 79(6):519-32.
Schwartz et al., Journal of Cellular Biochemistry, (1995) 58/Suppl. 22,(210-217).
Sepkovic et al., 2002, “Quantitative Determination of 3,3′-Diindolymethane in the urine of individuals receiving indole-3-carbinol,” Nutr Cancer. 2001;41(1-2):57-63.
Shilling et al., 2001, “3,3′-diindolylmethane, a major condensation product of indole-3-carbinol, is a potent estrogen in the rainbow trout,” Toxicology and Applied Pharmacology 170:191-200.
Stresser et al., 1995, “Mechanisms of tumor modulation by indole-3-carbinol: disposition and excretion in male fisher 344 rats,” Drug Metabolism and Disposition 23:965-975.
Stresser et al., 1995, “The anticarcinogen 3,3′-Diindolyl-methane is an inhibitor of cytochrome P-450,” J. Biochem. Toxicol., 10(4):191-201.
Tse et al., 1987, “Disposition of alpha-[(dimethylamino)methyl]-2-(3-ethyl-5-methyl-4-isoxazolyl)-1H-indole-3-methanol (59-801), a hypoglycaemic agent in rats, dogs and monkeys,” Xenobiotica, 17(6):741-9.
Walboomers et al., 1999, “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” J. Pathol. 189:12-19.
Bioresponse L.L.C.
Ebrahim Nabila
Hartley Michael G.
LandOfFree
Phytochemicals for the treatment of cervical dysplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phytochemicals for the treatment of cervical dysplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phytochemicals for the treatment of cervical dysplasia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800018